PLRZ
Polyrizon Ltd. Ordinary SharesPLRZ
PLRZ
About: Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.
–
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for PLRZ.
Financial journalist opinion
Based on 4 articles about PLRZ published over the past 30 days
Neutral
GlobeNewsWire
3 days ago
Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs
Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product development.
Neutral
GlobeNewsWire
4 days ago
Polyrizon's Moving Forward with Expected 2025 Clinical Trial - Entered Manufacturing Agreement for its PL-14 Allergy Blocker
The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts
Neutral
GlobeNewsWire
1 week ago
Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance
Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions.
Neutral
GlobeNewsWire
2 weeks ago
Polyrizon Enters into GMP Manufacturing Agreement for CTM Supply of its PL-14 Allergy Blocker in Preparation for Planned 2025 Clinical Trial
The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts
Neutral
Accesswire
1 month ago
Aegis Capital Corp. Acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ: PLRZ)
NEW YORK, NY / ACCESSWIRE / October 30, 2024 / Aegis Capital Corp. acted as Sole Bookrunner on a $4.2 Million (IPO) Initial Public Offering for Polyrizon Ltd. (NASDAQ:PLRZ).
Neutral
GlobeNewsWire
1 month ago
Polyrizon Announces Closing of $4.2 Million Initial Public Offering
Raanana, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels, today announced the closing of its underwritten initial public offering of 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share and three warrants to purchase one ordinary share per warrant, with an initial exercise price of $4.38 per share. Aggregate gross proceeds were $4.2 million, prior to deducting underwriting discounts and offering expenses.
Neutral
GlobeNewsWire
1 month ago
Polyrizon Announces Pricing of $4.2 Million Initial Public Offering and Listing on the Nasdaq Capital Market Under New Ticker “PLRZ”
Raanana, Israel, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (the "Company" or "PLRZ"), a development stage biotech company specializing in the development of innovative medical device hydrogels, today announced the pricing of its underwritten initial public offering of 958,903 units at a combined public offering price of $4.38 per unit, with each unit each consisting of one ordinary share and three warrants to purchase one ordinary share per warrant, with an initial exercise price of $4.38 per share. Aggregate gross proceeds are expected to be $4.2 million, prior to deducting underwriting discounts and offering expenses.
Charts implemented using Lightweight Charts™